Allergan Entertaining Offer From Actavis Over $200 Per Share

Bloomberg is reporting that Actavis plc (NYSE:ACT) is in talks to acquire Allergan, Inc. (NYSE:AGN) for a price north of $200 per share.  Allergan is said to want over $210 per share while Actavis is said to currently be willing to pay just over $200 per share, approximately a $3 billion gap in valuation, according to the report.

On November 7, when ValueWalk reported that Allergan was open to talks with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and other activists, we reported: “Insiders have indicated to ValueWalk that Allergan would  get the deal done for north of $200 per share, with statements by...